

Myogenin Antibody

Datasheet

For Research Use Only

Description	Catalog No.	Size
Myogenin Concentrate	FP-A063-01	0.1 ml
Myogenin Concentrate	FP-A063-05	1 ml
Myogenin Predilute	FP-A063-70	7 ml

Description

Myogenin belongs to a family of myogenic transcription factors, including MyoD, Myf5, and MRF4, which are critical in muscle development. Myogenin is found strictly in cells of skeletal muscle origin, and is therefore used as a biomarker for tumours of the muscle lineage, including alveolar rhabdomyosarcomas. AntiMyogenin staining may occur in Wilms' tumour, and it labels the nuclei of myoblasts in developing muscle tissue. It is also expressed in some leiomyosarcomas.

Specifications

Clone	IHC631
Source	Mouse Monoclonal
Applications	IHC (P)
Formulation	Tris Buffer, pH 7.3 - 7.7, with 1% BSA and <0.1% Sodium Azide

IHC Procedure*

Positive Control Tissue	Rhabdomyosarcoma
Concetrated Dilution	1:50 – 1:200
Pretreatment	Perform heat-induced epitope retrieval (HIER) at pH 9 for 10 to 30 minutes
Incubation Time and Temp	10 to 30 minutes at room temperature
Detection	Refer to the detection system manual

*Result should confirmed by an established diagnostic procedure.

Result




Figure. Myogenin on Rhabdomysarcoma

Storage and Handling

Must store the reagent at 2-8 °C. Do not freeze. Do not use the reagent after expiration date on vial. To ensure proper stability and delivery of the antibody after each run, replace the cap and immediately place the bottle in a refrigerator in an upright position. Positive and negative controls should be simultaneously run with unknown specimens, as there are no conclusive characteristics to suggest instability of the antibody.

Precautions

The product is for research use only. Do not use for diagnosis purpose. Ensure proper handling procedures are used with all reagents. Always wear laboratory coats, disposable gloves, and other appropriate laboratory equipment when handling reagents. Do not ingest reagents, and avoid contact with eyes and mucous membranes. Wash eyes with copious amounts of water if contact occurs.

References

1. **Zhu BL**, et al. "Changes of myocardial myoglobin, myosin and creatine kinase in cases of sudden nocturnal death syndrome." *Chin Med J (Engl)*. 1994; 107:36-40.
2. **Kock KF**, et al. "Renal myoglobin in drug addicts: occurrence and significance in a postmortem study." *Forensic Sci Int*. 1994 Mar 25;65(2):113-9.
3. **Horike K**, et al. "Relation between myoglobin and cardiac dysfunction in myocarditis--immunohistochemical study of endomyocardial biopsy specimens." *Jpn Circ J*. 1991; 55:24-32.
4. **Leader M**, et al. "Myoglobin: an evaluation of its role as a marker of rhabdomyosarcomas." *Br J Cancer*. 1989 Jan;59(1):106-9.
5. **Miller JB**, et al. "Myogenic programs of mouse muscle cell lines: expression of myosin heavy chain isoforms, MyoD1, and myogenin." *J Cell Biol*. 1990; 111:1149-59.
6. **Wang NP**, et al. "Expression of myogenic regulatory proteins (myogenin and MyoD1) in small blue round cell tumors of childhood." *Am J Pathol*. 1995; 147:1799-810.
7. **Cui S**, et al. "Evaluation of new monoclonal anti-MyoD1 and anti-myogenin antibodies for the diagnosis of rhabdomyosarcoma." *Pathol Int*. 1999 Jan;49(1):62-8.
8. **Cessna MH**, et al. "Are myogenin and myoD1 expression specific for rhabdomyosarcoma? A study of 150 cases, with emphasis on spindle cell mimics." *Am J Surg Pathol*. 2001 Sep;25(9):1150-7.
9. **Furlong MA**, et al. "Pleomorphic rhabdomyosarcoma in adults: a clinicopathologic study of 38 cases with emphasis on morphologic variants and recent skeletal muscle-specific markers." *Mod Pathol*. 2001 Jun;14(6):595-603.
10. **Dias P**, et al. "Strong immunostaining for myogenin in rhabdomyosarcoma is significantly associated with tumors of the alveolar subclass." *Am J Pathol*. 2000 Feb;156(2):399-408.



Technical Support

Contact FemtoPath Technical Support at +886232338585 or email to femtopath@hongjing.com.tw for questions regarding this product.